ESMO 2020 — Final OS analysis of abemaciclib plus tamoxifen for patients with HR+/HER2- metastatic breast cancer


  • Michael Simm
  • Oncology Conference reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Although the phase 2 nextMONARCH trial of women with heavily pretreated HR+/HER2- metastatic breast cancer was not powered to test superiority with regard to overall survival (OS), there was a statistically significant improvement of 7.2 months (24.2 vs. 17.0) with the addition of tamoxifen to abemaciclib compared to abemaciclib monotherapy.

Why this matters?

  • Abemaciclib is an oral, continuously dosed cyclin-dependendent kinase 4 & 6 inhibitor approved in the US and EU for patients with HR+/HER2- metastatic breast cancer (MBC) following progression from endocrine therapy (ET) alone.
  • A series of studies and have reported improved progression free survival (PFS) for abemaciclib in combination with endocrine therapy (MONARCH2, MONARCH3) or robust single-agent activity (nextMONARCH), but no OS data yet.

Study design

  • nextMONARCH was a multicenter randomized, open-label phase 2 trial of abemaciclib that enrolled 234 women with heavily pretreated HR+, HER2- MBC whose disease progressed on or after ET and chemotherapy.
  • Patients were randomized 1:1:1 to abemaciclib 150 mg + tamoxifen 20 mg (A), or abemaciclib 150 mg (B) or abemaciclib 200 mg plus prophylactic loperamide (C).
  • Funding: Eli Lilly and Company

Key results

  • Updated PFS at 183 events: A – 9.07 months, B – 7.20 months, C – 7.43 months. Hazard ratio (HR) A/C, 0.81 (not significant, P=.249)
  • Median OS A – 24.2 months, B – 20.8  months, C – 17.0 months. HR A/C, 0.62 (P=.034)
  • By adding loperamide, the incidence of grade 3 diarhea was reduced to 9% as compared to 20% in MONARCH1.

Follow all ESMO 2020 coverage on   Univadis .